Treatment of autoimmune diseases with engineered immune cells
AssigneeCaribou Biosciences, Inc.
InventorsSteven B. Kanner, George Kwong
Life of this patent
Estimating the term…
Abstract
The invention comprises methods and compositions for treating autoimmune diseases with engineered immune cells including cytotoxic T cells and natural killer (NK) cells. The engineered immune cells comprise a chimeric antigen receptor (CAR). Methods of making the engineered cells, methods of administration and treatment regimens are also disclosed.
Claims35
A method of treating an autoimmune disease in a patient, the method comprising:
- administering to the patient an amount of a composition comprising CD19-targeting engineered allogeneic CAR-T cells comprising:
- an anti-CD-19 CAR wherein the anti-CD19 CAR comprises FMC63, a CD8 hinge, a CD8 transmembrane domain, a 4-1BB co-stimulatory domain and a CD3 zeta signaling domain, and further comprising an inactivated PDCD1 gene, thereby improving one or more symptoms of the autoimmune disease in the patient.
(canceled)
5-13. (canceled)
(canceled)
20-26. (canceled)
(canceled)
(canceled)
32-35. (canceled)
A composition for treating an autoimmune disease comprising CD19-targeting allogeneic engineered CAR-T cells expressing a CAR comprising FMC63, a CD8 hinge, a CD8 transmembrane domain, a 4-1BB co-stimulatory domain and a CD3 zeta signaling domain, and further comprising an armoring genome modification comprising an inactivated PDCD1 gene, the cells being in the amount equivalent to 1/1000 of s dose used to treat B cell malignancies with the CD19-targeting engineered immune cells.
38-45. (canceled)
47-51. (canceled)
53-54. (canceled)
A method of treating an autoimmune disease in a patient, the method comprising:
- administering to the patient an amount of a composition comprising engineered allogeneic immune cells expressing an anti-CD19 CAR comprising FMC63, a CD8 hinge, a CD8 transmembrane domain, a 4-1BB co-stimulatory domain, and a CD3 zeta signaling domain, wherein the immune cells have been assessed for in vitro activity against B cells.
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.